Karyopharm Therapeutics INC Form 4 insider transactions

Karyopharm Therapeutics' EVP & Chief Commercial Officer, Sohanya Cheng, reported the vesting of performance-based restricted stock units and a subsequent tax-related stock sale.

Karyopharm Therapeutics' Chief Accounting Officer, Kristin Abate, reported the acquisition of shares from PSU vesting and a subsequent sale for tax obligations.

Karyopharm Therapeutics' Chief Accounting Officer, Kristin Abate, sold 12 shares of common stock to cover tax liabilities from restricted stock unit vesting.

Karyopharm Therapeutics Inc.'s EVP, Chief Development Officer, Stuart Poulton, sold 191 shares of common stock to cover tax liabilities from restricted stock unit vesting.

Karyopharm Therapeutics Inc.'s Chief Accounting Officer, Kristin Abate, filed a Form 4 indicating a future non-discretionary sale of 238 shares of common stock at $4 per share to cover tax liabilities from restricted stock unit vesting.

Karyopharm Therapeutics Inc. Director Zhen Su has acquired 4,600 nonstatutory stock options with an exercise price of $4.48, which will fully vest on May 28, 2026.

Karyopharm Therapeutics Inc. director Deepika Pakianathan was granted 4,600 nonstatutory stock options with an exercise price of $4.48, reflecting a recent reverse stock split.

Karyopharm Therapeutics Inc. director Christy J. Oliger acquired 4,600 nonstatutory stock options at an exercise price of $4.48, vesting fully on May 28, 2026, as reported in a recent SEC Form 4 filing.

Karyopharm Therapeutics Inc. Director Mansoor Raza Mirza was granted 4,600 nonstatutory stock options with an exercise price of $4.48, vesting fully on May 28, 2026, as disclosed in a recent SEC Form 4 filing.

Karyopharm Therapeutics Inc. Director Barry E. Greene has acquired 4,600 nonstatutory stock options with an exercise price of $4.48, which will fully vest on May 28, 2026.

Karyopharm Therapeutics Inc. Director Chen Schor reported the acquisition of 4,600 nonstatutory stock options with an exercise price of $4.48 per share, vesting fully on May 28, 2026.

Karyopharm Therapeutics Inc. Director Garen G. Bohlin was granted 4,600 nonstatutory stock options with an exercise price of $4.48 per share, vesting fully on May 28, 2026.

Richard Paulson, CEO of Karyopharm Therapeutics, sold 236 shares of common stock on May 6, 2025, to cover withholding tax liabilities related to vested restricted stock units.

Reshma Rangwala, EVP & Chief Medical Officer of Karyopharm Therapeutics, reports selling 419 shares of common stock to cover withholding tax liabilities.

Richard Paulson, CEO of Karyopharm Therapeutics, sold 245 shares of common stock to cover withholding tax liabilities.

Sohanya Cheng, EVP & Chief Commercial Officer of Karyopharm Therapeutics, sold 3,445 shares of common stock on March 4, 2025, to cover withholding tax liabilities.

Richard Paulson, CEO of Karyopharm Therapeutics, sold 11,694 shares of common stock to cover withholding tax liabilities from vesting restricted stock units.

Reshma Rangwala, EVP & Chief Medical Officer of Karyopharm Therapeutics, sold 3,587 shares of common stock on March 4, 2025, to cover withholding tax liabilities.

Stuart Poulton, EVP and Chief Development Officer of Karyopharm Therapeutics, sold 3,548 shares of common stock to cover withholding tax liabilities.

Kristin Abate, Chief Accounting Officer of Karyopharm Therapeutics, sold 571 shares of common stock on March 4, 2025, to cover withholding tax liabilities.

Michael Mano, SVP, General Counsel & Secretary of Karyopharm Therapeutics, reported selling 2,793 shares of common stock on March 4, 2025, to cover withholding tax liabilities.

Richard Paulson, CEO of Karyopharm Therapeutics, was granted stock options and restricted stock units (RSUs) on February 28, 2025, according to a Form 4 filing.

EVP & Chief Commercial Officer of Karyopharm Therapeutics, Sohanya Cheng, reports acquisition of stock and option awards following a reverse stock split.

Reshma Rangwala, EVP & Chief Medical Officer of Karyopharm Therapeutics, reports the acquisition of restricted stock units and stock options following a reverse stock split.

EVP and Chief Development Officer Stuart Poulton reports the acquisition of stock and option awards from Karyopharm Therapeutics Inc. following a reverse stock split.

Kristin Abate, Chief Accounting Officer of Karyopharm Therapeutics, reports the acquisition of stock options and restricted stock units (RSUs) following a one-for-fifteen reverse stock split.

Michael Mano, SVP, General Counsel & Secretary of Karyopharm Therapeutics, reports the acquisition of restricted stock units and stock options following a reverse stock split.

Stuart Poulton, EVP and Chief Development Officer of Karyopharm Therapeutics, sold 5,914 shares of common stock to cover withholding tax liability.

Richard Paulson, CEO of Karyopharm Therapeutics, sold 4,099 shares of common stock at $0.65 per share to cover withholding tax liabilities.

Karyopharm Therapeutics' CFO, Lori Macomber, received 160,000 restricted stock units and options to purchase 650,000 shares of common stock on January 31, 2025.